Expression of the Fas antigen on primary human leukemia cells.
The antigen defined by the monoclonal antibody anti-Fas can mediate apoptosis, is associated with the receptor for tumor necrosis factor, and is expressed on a limited number of human tissues. In this study we analyzed the expression of Fas on primary human leukemic cells and on mononuclear cells from other hematologic disorders. A total of 95 samples of blood or bone marrow were studied by indirect immunofluorescence. These samples included the normal controls, 47 cases of acute myelogenous leukemia (AML), 11 cases of acute lymphoblastic leukemia (ALL), 21 cases of leukemic lymphoma, seven cases of chronic myelogenous leukemia (CML), five cases of plasma cell leukemia or multiple myeloma, and five cases of myelodysplastic or myeloproliferative syndromes. Normal controls were negative without exception. Among AML, 13/47 cases (28%) were positive; among ALL, 1/11 cases (9%) was positive; among leukemic lymphomas, 3/21 cases (14%) were positive. In a case of plasma cell leukemia which strongly expressed the Fas antigen, we demonstrated that the antibody mediates cell lysis, which was synergistically enhanced by the addition of rabbit complement. In patients with AML, Fas positivity had no obvious clinical relevance. Taken together, our results show that approximately 30% of cases of AML and occasionally other leukemias express the Fas antigens, whereas normal controls are negative in our test system. These findings may be useful in the treatment of refractory leukemias or may permit the purging of autologous transplants.
Munker
R
R
Medizinische Klinik III, Universitätsklinikum Grosshadern, Ludwig-Maximilians-Universität, Munich, Germany.
Lübbert
M
M
Yonehara
S
S
Tuchnitz
A
A
Mertelsmann
R
R
Wilmanns
W
W
D000954:Antigens, Surface / Q000032:analysis / Q000502:physiology*; D017209:Apoptosis; D001853:Bone Marrow / Q000276:immunology* / Q000473:pathology; D005455:Fluorescent Antibody Technique; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D007952:Leukemia, Plasma Cell / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D009101:Multiple Myeloma / Q000175:diagnosis / Q000276:immunology / Q000473:pathology; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology; D011379:Prognosis; D019014:fas Receptor
D000954:Antigens, Surface; D019014:fas Receptor